|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...2425262728293031323334...6566» |
- || Synflorix (10-valent pneumococcal conjugate vaccine) / GSK
Enrollment change: Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=622, Completed, Sponsor: GlaxoSmithKline
N=512 --> 622
- |||| Trial completion, Trial primary completion date: Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV (clinicaltrials.gov) - Apr 20, 2015
P2, N=120, Completed, Sponsor: Lisichansk Regional Tuberculosis Dispensary
N=512 --> 622 Enrolling by invitation --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date: LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study (clinicaltrials.gov) - Apr 19, 2015
P0, N=60, Suspended, Sponsor: CDA Research Group, Inc.
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- || vancomycin / Generic mfg.
Trial primary completion date: Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation (clinicaltrials.gov) - Apr 19, 2015
P2, N=86, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- New trial: Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (clinicaltrials.gov) - Apr 17, 2015
P=N/A, N=257, Completed, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- | Trial completion, Trial primary completion date, Combination therapy: TESEC-07: Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses (clinicaltrials.gov) - Apr 17, 2015
P2/3, N=456, Completed, Sponsor: Statens Serum Institut
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Sep 2014
- | Trial completion, Trial primary completion date, Combination therapy: A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI (clinicaltrials.gov) - Apr 17, 2015
P3, N=1190, Completed, Sponsor: Statens Serum Institut
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Sep 2014 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Sep 2014
- ||| AERAS-404 / Sanofi
New P1 trial: C-013-404: A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults (clinicaltrials.gov) - Apr 17, 2015
P1, N=70, Completed, Sponsor: Aeras
- | Trial completion, Trial primary completion date, Combination therapy: Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI (clinicaltrials.gov) - Apr 17, 2015
P3, N=979, Completed, Sponsor: Statens Serum Institut
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Sep 2014 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014
- Trial completion: Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=161, Completed, Sponsor: E-DA Hospital
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014 Recruiting --> Completed
- Trial primary completion date: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (clinicaltrials.gov) - Apr 15, 2015
P2, N=40, Recruiting, Sponsor: Michael Boyle
Recruiting --> Completed Trial primary completion date: Mar 2015 --> Mar 2016
- || PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment status: Post Market Surveillance to Observe Safety of Prevenar13™ in Adults (clinicaltrials.gov) - Apr 15, 2015
P4, N=600, Recruiting, Sponsor: Pfizer
Trial primary completion date: Mar 2015 --> Mar 2016 Enrolling by invitation --> Recruiting
- |||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Trial primary completion date: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Apr 15, 2015
P3, N=750, Recruiting, Sponsor: Novartis
Enrolling by invitation --> Recruiting Trial primary completion date: Apr 2016 --> Aug 2016
- || Trial primary completion date, HEOR: Impact of Rapid Detection of MRSA (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=240, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2016 --> Aug 2016 Trial primary completion date: Dec 2014 --> Jul 2015
- Trial primary completion date: Determining the Impact of Enhanced Case Finding on Tuberculosis Notification in The Gambia (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=650000, Recruiting, Sponsor: Medical Research Council Unit, The Gambia
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment closed: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=1927, Active, not recruiting, Sponsor: University Hospital, Geneva
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- Enrollment change: Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 (clinicaltrials.gov) - Apr 14, 2015
P1, N=32, Completed, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Recruiting --> Active, not recruiting N=24 --> 32
- amikacin/fosfomycin inhalation (AFIS) / Savara
Trial primary completion date, Gram positive, Gram negative: Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization (clinicaltrials.gov) - Apr 14, 2015
P2, N=14, Recruiting, Sponsor: Cardeas Pharma
N=24 --> 32 Trial primary completion date: Mar 2015 --> Dec 2015
- || amikacin/fosfomycin inhalation (AFIS) / Savara
Trial primary completion date, Gram negative: Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia (clinicaltrials.gov) - Apr 14, 2015
P2, N=150, Recruiting, Sponsor: Cardeas Pharma
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- ||||| New P2 trial: C-010-402: A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB (clinicaltrials.gov) - Apr 13, 2015
P2, N=72, Completed, Sponsor: Aeras
- | Enrollment open, Trial initiation date, Trial primary completion date: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - Apr 13, 2015
P4, N=35, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Dec 2015 --> Apr 2016
- Trial completion, Enrollment change: Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda (clinicaltrials.gov) - Apr 13, 2015
P=N/A, N=540, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed | N=250 --> 540
- GSK4069327A / LimmaTech Biologics
Enrollment closed: Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a (clinicaltrials.gov) - Apr 12, 2015
P1, N=30, Active, not recruiting, Sponsor: GlycoVaxyn AG
Active, not recruiting --> Completed | N=250 --> 540 Recruiting --> Active, not recruiting
- rifampicin / Generic mfg.
Phase classification: Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers (clinicaltrials.gov) - Apr 11, 2015
P1, N=18, Recruiting, Sponsor: National University Hospital, Singapore
Recruiting --> Active, not recruiting Phase classification: P2 --> P1
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment closed: Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) (clinicaltrials.gov) - Apr 10, 2015
P4, N=240, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P1 Recruiting --> Active, not recruiting
- clindamycin phosphate / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion, Trial primary completion date: Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus (clinicaltrials.gov) - Apr 10, 2015
P2, N=1310, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Feb 2015
- Tice BCG (live attenuated bacillus Calmette-Guerin) / Merck (MSD), Texas A&M University
New trial: Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US (clinicaltrials.gov) - Apr 10, 2015
P0, N=12, Not yet recruiting, Sponsor: Aeras
- ||||||| Cayston (aztreonam lysine) / Gilead
Trial completion, Enrollment change, Trial primary completion date: AZLI CAT: Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (clinicaltrials.gov) - Apr 10, 2015
P3, N=90, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Feb 2015 Active, not recruiting --> Completed | N=250 --> 90 | Trial primary completion date: Jun 2015 --> Jan 2015
- Enrollment change: Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis (clinicaltrials.gov) - Apr 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: Medical Research Council Unit, The Gambia
Active, not recruiting --> Completed | N=250 --> 90 | Trial primary completion date: Jun 2015 --> Jan 2015 N=120 --> 0
- || Enrollment closed: Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis (clinicaltrials.gov) - Apr 9, 2015
P=N/A, N=51, Active, not recruiting, Sponsor: Manresana de Micobacteriologia, SL
N=120 --> 0 Completed --> Active, not recruiting
- | Trial completion: FASTFOOD: HRZE Fasted/Fed in Newly Diagnosed TB (clinicaltrials.gov) - Apr 8, 2015
P2, N=20, Completed, Sponsor: University Medical Centre Groningen
Completed --> Active, not recruiting Recruiting --> Completed
- Trial completion, Enrollment change: PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=195, Completed, Sponsor: Regionshospitalet Viborg, Skive
Recruiting --> Completed Recruiting --> Completed | N=150 --> 195
- | levofloxacin / Generic mfg., ceftaroline fosamil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Apr 8, 2015
P4, N=12, Completed, Sponsor: Gary E. Stein, Pharm.D.
Recruiting --> Completed | N=150 --> 195 Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2014 --> May 2014
- |||| azithromycin / Generic mfg.
Trial completion, Licensing / partnership, Enrollment change: PRET: Partnership for Rapid Elimination of Trachoma (clinicaltrials.gov) - Apr 7, 2015
P4, N=20586, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2014 --> May 2014 Enrolling by invitation --> Completed | N=15000 --> 20586
- | Trial completion: VHA Clinicians and Bioterror Events: Interactive Web-based Learning (clinicaltrials.gov) - Apr 5, 2015
P=N/A, N=15, Completed, Sponsor: Department of Veterans Affairs
Enrolling by invitation --> Completed | N=15000 --> 20586 No longer recruiting --> Completed
- ||| PF-06290510 / Pfizer
Trial completion: Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years (clinicaltrials.gov) - Apr 3, 2015
P1, N=100, Completed, Sponsor: Pfizer
No longer recruiting --> Completed Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Vouchers to Promote Tdap Vaccination (clinicaltrials.gov) - Apr 3, 2015
P0, N=149, Completed, Sponsor: Children's Hospital of Philadelphia
Recruiting --> Completed Active, not recruiting --> Completed | N=240 --> 149 | Trial primary completion date: Dec 2013 --> Mar 2014
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Phase classification: VARIANT: Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis (clinicaltrials.gov) - Apr 2, 2015
P2, N=626, Not yet recruiting, Sponsor: Alfa Wassermann S.p.A.
Active, not recruiting --> Completed | N=240 --> 149 | Trial primary completion date: Dec 2013 --> Mar 2014 Phase classification: P2/3 --> P2
- Enrollment open, Trial initiation date: D-STAPH: Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers (clinicaltrials.gov) - Apr 1, 2015
P2, N=300, Recruiting, Sponsor: Peter Bergman
Phase classification: P2/3 --> P2 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014
- | rifampicin / Generic mfg.
Enrollment open, Trial initiation date: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Mar 31, 2015
P2/3, N=60, Recruiting, Sponsor: Universitas Padjadjaran
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Dec 2014
- ||||| ilaprazole / Generic mfg., amoxicillin / Generic mfg.
New P4 trial: Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection (clinicaltrials.gov) - Mar 27, 2015
P4, N=90, Recruiting, Sponsor: Il-Yang Pharm. Co., Ltd.
- cefixime / Generic mfg.
Trial completion: The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study (clinicaltrials.gov) - Mar 27, 2015
P1, N=25, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Dec 2014 Recruiting --> Completed
- efavirenz / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=63, Terminated, Sponsor: Instituto Nacional de Enfermedades Respiratorias
Recruiting --> Completed N=160 --> 63 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Feb 2011; Other published trials showed definitive expected superiority of Group 1
- cyclosporin A microemulsion / Generic mfg.
Trial completion, Enrollment change, Trial initiation date: Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum (clinicaltrials.gov) - Mar 26, 2015
P2, N=20, Completed, Sponsor: London School of Hygiene and Tropical Medicine
N=160 --> 63 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Feb 2011; Other published trials showed definitive expected superiority of Group 1 Not yet recruiting --> Completed | N=12 --> 20 | Initiation date: Aug 2009 --> Aug 2010
- ||| Clinical: Scrub Typhus Pediatric Immunology Study (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=170, Not yet recruiting, Sponsor: University of Oxford
- || Altabax (retapamulin) / GSK, Almirall
Enrollment closed: ALTARGOPMS: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=3000, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed | N=12 --> 20 | Initiation date: Aug 2009 --> Aug 2010 Recruiting --> Active, not recruiting
- ethambutol / Generic mfg., clarithromycin / Generic mfg.
Trial completion: Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease (clinicaltrials.gov) - Mar 25, 2015
P2, N=50, Completed, Sponsor: National Jewish Center for Immnunology & Respiratory Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection (clinicaltrials.gov) - Mar 25, 2015
P3, N=174, Completed, Sponsor: IWK Health Centre
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Study of Human Botulism Immunoglobulin in Infants With Botulism (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=120, Completed, Sponsor: California Department of Health Services
Active, not recruiting --> Completed Recruiting --> Completed
- ||| rifampicin / Generic mfg.
Enrollment closed: Trial of High-Dose Rifampin in Patients With TB (clinicaltrials.gov) - Mar 24, 2015
P2, N=180, Active, not recruiting, Sponsor: Harvard University Faculty of Medicine
Recruiting --> Completed Recruiting --> Active, not recruiting